EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Repeated HLA ‐ DRB1 and HLA ‐ DQB1 Mismatches Without Preformed DSA Affect Graft Survival, Rejection and DSA Development: A Multicenter Analysis

D A J van den Broek iD, S Meziyerh iD, D van der Helm iD, J C van den Born iD, J S F Sanders iD, B G Hepkema iD, J van de Wetering iD, J A Kal van Gestel iD, J Kers iD, C van Kooten iD, J I Rotmans iD, A P J de Vries iD und 1 weitere

HLA · 2025-05 · 105 (5)

DOI: 10.1111/tan.70264 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift HLA, online erschienen am 19.05.2025. Verfasst von D A J van den Broek und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Internal Medicine, Leiden University Medical Center (LUMC), Leiden University, Leiden, the Netherlands. Hauptthemen laut MEDLINE: Graft Rejection, HLA-DQ beta-Chains, Kidney Transplantation, HLA-DRB1 Chains. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Repeat transplantations represent up to 20% of all kidney transplants. Whereas repeat transplantations in the presence of circulating donor‐specific HLA‐antibodies are generally avoided, the risk of repeated HLA‐mismatches (RMM) without detectable antibodies remains debated. This multicenter study evaluated the hazard of RMM, stratified by HLA‐class, on transplant outcomes in the absence of preformed donor‐specific antibodies. We included repeat kidney transplant recipients from January 2009 onward with available HLA typing for HLA‐A, ‐B, ‐C, ‐DRB1, ‐DRB3/4/5 and ‐DQB1 from current and previous donors. RMM were defined at the split serological antigen level, excluding patients with only HLA‐DP or HLA‐DRB3/4/5 RMM. Patients were included if: (a) preformed donor‐specific HLA‐antibodies (DSA) had never been detected and (b) this was confirmed by Luminex assays within 6 months pre‐transplantation. A competing risk model, adjusting for demographic factors and total HLA‐mismatch load while accounting for death as a competing risk, showed that HLA‐DRB1 and/or HLA‐DQB1 RMM significantly increased the risk of graft loss within 1 year post‐transplant (HR 3.75 [95% CI 1.51–9.34], p = 0.004). Cox proportional hazard models further linked these HLA‐class II RMM to higher risks of biopsy‐proven rejection (HR 1.98 [95% CI 1.04–3.76], p = 0.037) and DSA development (HR 9.89 [95% CI 1.92–50.99], p = 0.006), while no significant risks were observed for HLA‐class I RMM. Sensitivity analyses in patients screened for pretransplant DSA via single antigen bead assays, those with similar immunosuppression, and those with allelic RMM further confirmed these findings. These results suggest that avoiding HLA‐DRB1 and HLA‐DQB1 RMM, when feasible, may improve transplant outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Graft RejectionHLA-DQ beta-ChainsKidney TransplantationHLA-DRB1 ChainsGraft SurvivalIsoantibodiesHumansFemaleMaleMiddle AgedHistocompatibility TestingAdult

Stichwörter der Autor:innen

HLAallograft survivalrejectionrenal transplantationrepeated mismatchrisk‐stratificationsensitization

Substanzen

HLA-DQ beta-ChainsHLA-DQB1 antigenHLA-DRB1 ChainsIsoantibodies

Autor:innen und Institutionen

  • Division of Nephrology, Department of Internal Medicine, Leiden University Medical Center (LUMC), Leiden University, Leiden, the Netherlands.
  • Leiden Transplant Center, Leiden University Medical Center (LUMC), Leiden University, Leiden, the Netherlands.
  • Department of Internal Medicine, Division of Nephrology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
  • Transplantation Immunology, Department of Laboratory Medicine, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • Department of Internal Medicine, Erasmus Medical Center Transplant Institute, University Medical Center, Rotterdam, the Netherlands.
  • Department of Pathology, Leiden University Medical Center (LUMC), Leiden, the Netherlands.

ORCID-Profile: D A J van den Broek, S Meziyerh, D van der Helm, J C van den Born, J S F Sanders, B G Hepkema, J van de Wetering, J A Kal van Gestel, J Kers, C van Kooten, J I Rotmans, A P J de Vries, D L Roelen

Zitieren

APA

van den Broek, D. A. J., Meziyerh, S., van der Helm, D., van den Born, J. C., Sanders, J. S. F., Hepkema, B. G., van de Wetering, J., van Gestel, J. A. K., Kers, J., van Kooten, C., Rotmans, J. I., de Vries, A. P. J., & Roelen, D. L. (2025). Repeated HLA ‐ DRB1 and HLA ‐ DQB1 Mismatches Without Preformed DSA Affect Graft Survival, Rejection and DSA Development: A Multicenter Analysis. HLA, 105(5). https://doi.org/10.1111/tan.70264

Vancouver

van den Broek DAJ, Meziyerh S, van der Helm D, van den Born JC, Sanders JSF, Hepkema BG, et al. Repeated HLA ‐ DRB1 and HLA ‐ DQB1 Mismatches Without Preformed DSA Affect Graft Survival, Rejection and DSA Development: A Multicenter Analysis. HLA. 2025;105(5). doi:10.1111/tan.70264

BibTeX
@article{vandenBroek2025,
  author = {van den Broek, D A J and Meziyerh, S and van der Helm, D and van den Born, J C and Sanders, J S F and Hepkema, B G and van de Wetering, J and van Gestel, J A Kal and Kers, J and van Kooten, C and Rotmans, J I and de Vries, A P J and Roelen, D L},
  title = {Repeated HLA ‐ DRB1 and HLA ‐ DQB1 Mismatches Without Preformed DSA Affect Graft Survival, Rejection and DSA Development: A Multicenter Analysis},
  journal = {HLA},
  year = {2025},
  volume = {105},
  number = {5},
  doi = {10.1111/tan.70264}
}
Kostenlos starten →